Skip to main content

Table 2 Risk factors for PJP occurrence in IIM patients

From: High incidence and mortality of Pneumocystis jirovecii infection in anti-MDA5-antibody-positive dermatomyositis: experience from a single center

Variable

Univariable

Multivariable

OR (95% CI)

P value

OR (95% CI)

P value

Corticosteroid dose, mg

1.005 (0.999, 1.012)

0.117

-

0.703

Corticosteroid (≥20 mg, ≥ 1 month)

1.76 (0.581, 5.335)

0.317

*

*

Diabetes

4.758 (1.596, 14.186)

0.005

-

0.067

Tacrolimus

2.865 (0.869, 9.451)

0.084

-

0.616

Mycophenolate mofetil

1.157 (0.146, 9.162)

0.890

*

*

Ciclosporin

2.027 (0.619, 6.637)

0.243

*

*

Cyclophosphamide

0.809 (0.103, 6.347)

0.840

*

*

Methotrexate

0.000 (0.000, 0.000)

0.998

*

*

Biological agent

0.000 (0.000, 0.000)

0.999

*

*

MDA5+ DM

12.203 (2.696, 55.229)

0.001

6.374 (1.368, 29.722)

0.018

Age

1.006 (0.963, 1.050)

0.790

*

*

Interstitial lung disease

5.472 (0.709, 42.249)

0.103

-

0.742

Erythrocyte sedimentation rate

1.001 (0.997, 1.005)

0.659

*

*

Lactic dehydrogenase

1.000 (1.000, 1.001)

0.269

*

*

CD4 + T cell counts at admission

0.991 (0.985, 0.996)

0.001

0.986 (0.992, 0.997)

0.003

Lymphocyte counts at admission

0.099 (0.019, 0.522)

0.006

-

0.589

Disease duration, months, median

0.763 (0.600, 0.970)

0.027

-

0.066

Albumin

0.844 (0.761, 0.937)

0.001

-

0.667

  1. CI confidence interval
  2. *Not included in the multivariable model due to the lack of significant association in the univariable analysis
  3. - Included in the multivariable model but lacking of significant association in the multivariate analysis